Nanobiotix S.A. (NBTX), a late-clinical-stage biotechnology company, reported financial results for the year ended December 31, 2025, reflecting a narrower net loss and provided cash runway guidance.
Following the news, NBTX is down 2.59% at $30.07 in the overnight market.
Company Profile
Nanobiotix develops nanotherapeutic product candidates primarily for cancer treatment.
Its lead product investigational candidate, JNJ-1900 (NBTXR3), is designed for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, oesophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialise NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Full Year 2025 Results and Guidance
For the full year 2025, net loss attributable to shareholders narrowed to 23.96 million Euros, or 0.50 Euros per share, from 68.13 million Euros, or 1.44 Euros per share.
The firm recorded revenue and other income of 32.59 million Euros in 2025, compared to a negative 7.19 million Euros in the prior year, which included a one-off positive revenue recognition impact of 21.8 million Euros in accordance with IFRS15 application.
In the fourth quarter of 2025,Nanobiotix announced strategic non-dilutive royalty monetization agreement with HealthCare Royalty for JNJ-1900 (NBTXR3) for up to $71 million and $50 million was already received in December 2025.
As of December 31, 2025, Nanobiotix had 52.8 million Euros in cash and cash equivalents, and assuming receipt of the remaining $21 million in funding from HealthCare Royalty, expected one-year post-closing upon meeting certain conditions the firm expects this to fund its operations into early 2028.
Clinical data readouts from Phase 1 and 2 studies for JNJ-1900 (NBTXR3) are expected in 2026 from in NSCLC (re-irradiation), pancreatic cancer, melanoma and oesophageal cancer.
"With a strengthened financial position and anticipated clinical updates on the horizon, we believe Nanobiotix is strongly positioned to deliver continued momentum and meaningful impact in 2026 and beyond," said Laurent Levy, co-founder of Nanobiotix.
The firm also announced the filing of its universal registration document 0r URD with the French financial market authority as well as the annual report on Form 20-F with the U.S. Securities and Exchange Commission.
NBTX has traded between $2.99 and $41.89 in the last year. The stock closed Tuesday's trade at $30.87, up 0.95%.
For More Such Biotech and Pharmaceutical News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.